Advertisement
UK markets close in 5 hours 49 minutes

  • FTSE 100

    8,357.63
    +3.58 (+0.04%)
     

  • FTSE 250

    20,479.26
    -12.73 (-0.06%)
     

  • AIM

    781.55
    +1.72 (+0.22%)
     

  • GBP/EUR

    1.1631
    +0.0008 (+0.07%)
     

  • GBP/USD

    1.2480
    -0.0018 (-0.14%)
     

  • Bitcoin GBP

    48,849.95
    -914.92 (-1.84%)
     

  • CMC Crypto 200

    1,317.00
    +16.90 (+1.30%)
     

  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     

  • DOW

    39,056.39
    +172.13 (+0.44%)
     

  • CRUDE OIL

    79.44
    +0.45 (+0.57%)
     

  • GOLD FUTURES

    2,316.10
    -6.20 (-0.27%)
     

  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     

  • HANG SENG

    18,537.81
    +223.95 (+1.22%)
     

  • DAX

    18,542.70
    +44.32 (+0.24%)
     

  • CAC 40

    8,118.09
    -13.32 (-0.16%)
     
Money:

Bank of England expected to hold interest rates

Investors predict MPC will maintain interest at 5.25% when it meets on Thursday.

Innoviva (INVA) Dips More Than Broader Markets: What You Should Know

Zacks Equity Research
·2-min read

In the latest trading session, Innoviva (INVA) closed at $14.36, marking a -1.64% move from the previous day. This move lagged the S&P 500's daily loss of 0.21%. At the same time, the Dow lost 0.58%, and the tech-heavy Nasdaq lost 0.46%.

INVA will be looking to display strength as it nears its next earnings release. In that report, analysts expect INVA to post earnings of $0.32 per share. This would mark a year-over-year decline of 5.88%.

Any recent changes to analyst estimates for INVA should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

ADVERTISEMENT

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 12.74% higher. INVA currently has a Zacks Rank of #1 (Strong Buy).

Looking at its valuation, INVA is holding a Forward P/E ratio of 8.25. This valuation marks a discount compared to its industry's average Forward P/E of 14.48.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 13, putting it in the top 6% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Innoviva, Inc. (INVA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.